Abstract
Cardiovascular disease (CVD) risk factors, such as arterial hypertension, obesity, dyslipidemia or diabetes mellitus, as well as CVDs, including myocardial infarction, coronary artery disease or stroke, are the most prevalent diseases and account for the major causes of death worldwide. In the present study, 4,709 unrelated patients subjected to CVD panel in south-east part of Turkey between the years 2010 and 2013 were enrolled and DNA was isolated from the blood samples of these patients. Mutation analyses were conducted using the real-time polymerase chain reaction method to screen six common mutations (Factor V G1691A, PT G20210A, Factor XIII V34L, MTHFR A1298C and C677T and PAI-1 −675 4G/5G) found in CVD panel. The prevalence of these mutations were 0.57, 0.25, 2.61, 13.78, 9.34 and 24.27 % in homozygous form, respectively. Similarly, the mutation percent of them in heterozygous form were 7.43, 3.44, 24.91, 44.94, 41.09 and 45.66 %, respectively. No mutation was detected in 92 (1.95 %) patients in total. Because of the fact that this is the first study to screen six common mutations in CVD panel in south-east region of Turkey, it has a considerable value on the diagnosis and treatment of these diseases. Upon the results of the present and previous studied a careful examination for these genetic variants should be carried out in thrombophilia screening programs, particularly in Turkish population.
Similar content being viewed by others
References
Sheweita SA, Baghdadi H, Allam AR (2011) Role of genetic changes in the progression of cardiovascular diseases. Int J Biomed Sci 7(4):238–248
Torabi R, Zarei S, Zeraati H, Zarnani AH, Akhondi MM, Hadavi R, Shiraz ES, Jeddi-Tehrani M (2012) Combination of thrombophilic gene polymorphisms as a cause of increased the risk of recurrent pregnancy loss. J Reprod Infertil 13(2):89–94
Tug E, Aydin H, Kaplan E, Dogruer D (2011) Frequency of genetic mutations associated with thromboembolism in the Western Black Sea Region. Intern Med 50(1):17–21
Ridker PM, Miletich JP, Hennekens CH, Buring JE (1997) Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 277(16):1305–1307
Gregg JP, Yamane AJ, Grody WW (1997) Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet 73(3):334–336
De Stefano V, Chiusolo P, Paciaroni K, Leone G (1998) Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 24(4):367–379
Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79(4):706–708
Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR (1997) The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population. Br J Haematol 98(2):353–355
Trumbo TA, Maurer MC (2000) Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem 275(27):20627–20631
Muszbek L, Ariëns RA, Ichinose A (2007) Factor XIII: recommended terms and abbreviations. J Thromb Haemost 5(1):181–183
Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R (1994) Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet 7(4):551
Sibani S, Christensen B, O’Ferrall E, Saadi I, Hiou-Tim F, Rosenblatt DS, Rozen R (2000) Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. Hum Mutat 15(3):280–287
van der Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural tube defects? Am J Hum Genet 62(5):1044–1051
Balta G, Altay C, Gurgey A (2002) PAI-1 gene 4G/5G genotype: a risk factor for thrombosis in vessels of internal organs. Am J Hematol 71(2):89–93
Falcão-Pires I, Leite-Moreira AF (2012) Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 17(3):325–344
Ajabnoor MA, AL-Ama MN, Banjar Z, Rafee AA, Sheweita SA (2003) Homocysteine level and other biochemical parameters in cardiovascular disease patients with diabetes mellitus. Med Sci Monit 9(12):7–532
Chen Q, Reis SE, Kammerer C, Craig W, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CN, Kamboh MI (2011) Association of antioxidized LDL and candidate genes with severity of coronary stenosis in the Women’s Ischemia Syndrome Evaluation study. J Lipid Res 52(4):801–807
Reitsma PH (2000) Genetic heterogeneity in hereditary thrombophilia. Haemostasis 30(Suppl 2):1–10
Altintas A, Pasa S, Akdeniz N, Cil T, Yurt M, Ayyildiz O, Batun S, Isi H (2007) Factor V Leiden and G20210A prothrombin mutations in patients with recurrent pregnancy loss: data from the southeast of Turkey. Ann Hematol 86(10):727–731
Lindqvist PG, Dahlback B (2008) Carriership of factor V Leiden and evolutionary selection advantage. Curr Med Chem 15(15):1541–1544
Dahlback B (2008) Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 112(1):19–27
Akar N, Akar E, Dalgın G, Sozuoz A, Omurlu K, Cin S (1997) Frequency of Factor V (1691 G-A) mutation in Turkish population. Thromb Haemost 78(6):1527–1528
Makris M (2009) Thrombophilia: grading the risk. Blood 113(21):5038–5039
They-They TP, Battas O, Slassi I, Rafai MA (2012) KatumbayDT, Nadifi S. Prothrombin G20210A and factor V Leiden polymorphisms in stroke. J Mol Neurosci 46(1):210–216
Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79(4):706–708
Nguyen A (2000) Prothrombin G20210A polymorphism and thrombophilia. Mayo Clin Proc 75(6):595–604
Heng CK, Lal S, Saha N, Low PS, Kamboh MI (2004) The impact of factor XIIIa V34L polymorphism on plasma factor XIII activity in the Chinese and Asian Indians from Singapore. Hum Genet 114(2):186–191
Mahfouz RA, Sabbagh AS, Shammaa DM, Otrock ZK, Zaatari GS, Taher AT (2008) Factor XIII gene V34L mutation in the Lebanese population: another unique feature in this community? Mol Biol Rep 35(3):375–378
Thomas P, Fenech M (2008) Methylenetetrahydrofolate reductase, common polymorphisms, and relation to disease. Vitam Horm 79:375–392
Homberger A, Linnebank M, Winter C, Willenbring H, Marquardt T, Harms E, Koch HG (2000) Genomic structure and transcript variants of the human methylenetetrahydrofolate reductase gene. Eur J Hum Genet 8(9):725–729
Rady PL, Tyring SK, Hudnall SD, Vargas T, Kellner LH, Nitowsky H, Matalon RK (1999) Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet 86(4):380–384
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111–113
Sazci A, Ergul E, Kaya G, Kara I (2005) Genotype and allele frequencies of the polymorphic methylenetetrahydrofolate reductase gene in Turkey. Cell Biochem Funct 23(1):51–54
Ozmen F, Ozmen MM, Ozalp N, Akar N (2009) The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. Ulus Travma Acil Cerrahi Derg 15(2):113–119
Sotiriadis A, Vartholomatos G, Pavlou M, Kolaitis N, Dova L, Stefos T, Paraskevaidis E, Kalantaridou SN (2007) Combined thrombophilic mutations in women with unexplained recurrent miscarriage. Am J Reprod Immunol 57(2):133–141
Kim KN, Kim KM, Kim BT, Joo NS, Cho DY, Lee DJ (2012) Relationship of plasminogen activator inhibitor 1 gene 4G/5G polymorphisms to hypertension in Korean women. Chin Med J (Engl) 125(7):1249–1253
Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, Oberkanins C, Moritz A, Krugluger W, Huber J, Hopmeier P (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081–1086
Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, Grobbee DE (2000) Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 101(1):67–70
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oztuzcu, S., Ergun, S., Ulaşlı, M. et al. Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey. Mol Biol Rep 41, 3671–3676 (2014). https://doi.org/10.1007/s11033-014-3231-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-014-3231-5